Shanghai Nanhai Pharmaceutical Co., Ltd., a controlling shareholder of 2 billion capital increase

On November 16, Hainan Haiyao announced that Xinxing International Pharmaceutical Co., Ltd plans to gain control over Hainan Haiyao by means of cash capital increase in Nanfang Tongzheng, with the capital increase amount not exceeding 2 billion yuan It is understood that Xinxing International Pharmaceutical Co., Ltd is a wholly-owned subsidiary of Xinxing International Pharmaceutical Group, which is directly supervised by the SASAC of the State Council According to the agreement disclosed on December 16, the actual controller of Hainan Haiyao has acknowledged that he has made commitments to the future product listing and R & D Progress of Hainan Haiyao: Shanghai lisengte Medical Technology Co., Ltd., which is held by Hainan Haiyao, will complete the registration and listing of the second generation cochlear implant system products by December 31, 2020; China antibody Pharmaceutical Co., Ltd., which is invested by Hainan Haiyao, will By December 31, 2020, at least one new monoclonal antibody class 1 drug product will be approved for listing, and by the end of 2019, China antibody Pharmaceutical Co., Ltd will be listed; Shanghai youcadi Biomedical Technology Co., Ltd., which promises to invest in Hainan Haiyao, will have at least two new chimeric antigen receptor T-cell therapy (car-t) class 1 drug products obtained clinical approval documents by December 31, 2019 In addition, according to the 2018 semi annual report of Hainan Haiyao, the company realized operating revenue of RMB 1.153 billion in the first half of the year, a year-on-year increase of 51.06%; net profit attributable to shareholders of listed companies was RMB 150 million, a year-on-year increase of 31.61% The following is the full text of the announcement: